Epioxa

Epioxa is a clinical-stage biotechnology company pioneering the development of novel compounds that target the enteric nervous system to treat neurodegenerative and endocrine-related diseases. Rebranded from Enterin in early 2024, the company focuses on the gut-brain axis, specifically the role of alpha-synuclein aggregation in the gastrointestinal tract as a driver of Parkinson's disease. Their lead asset, ENT-01, is a synthetic squalamine derivative designed to displace alpha-synuclein from nerve cells in the gut, which has shown clinical efficacy in improving both bowel function and neurologic symptoms. Epioxa's approach represents a shift in neurology toward early intervention via the peripheral nervous system to prevent or slow disease progression in the brain. The company is also expanding its pipeline to address conditions such as Dementia with Lewy Bodies and metabolic disorders.